Nimodipine microparticles - Edge Therapeutics

Drug Profile

Nimodipine microparticles - Edge Therapeutics

Alternative Names: EG-1962; NimoVent; Polymeric nimodipine microparticle

Latest Information Update: 04 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Edge Therapeutics
  • Class Antihaemorrhagics; Antihypertensives; Dihydropyridines; Esters; Nicotinic-acids
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • New Molecular Entity No
  • Available For Licensing Yes - Brain injuries; Cerebral ischaemia

Highest Development Phases

  • Phase III Cerebral ischaemia

Most Recent Events

  • 27 Jun 2018 Efficacy data from a phase III NEWTON 2 trial in Cerebral ischaemia released by Edge Therapeutics
  • 24 Jun 2018 Biomarkers information updated
  • 04 Apr 2018 Edge Therapeutics terminates a phase I trial in Cerebral ischaemia (Prevention) in USA (Intracisternal) (NCT02893826)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top